Bladder Cancer

New Protocol: Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer

2023-04-14

  • Study

    Multicenter, open-label, phase 1/2 trial
    Cisplatin ineligible local advanced/metastatic urothelial carcinoma
    Enfortumab vedotin +pembrolizumab q21 (n=45)


  • Efficacy

    CRR: 15.6% [7 of 45 pts]
    ORR: 73.3% [33 of 45 pts]
    mDOR: 25.6 mos [8.28-NR]
    mPFS: 12.3 mos [7.98-NR]
    mOS: 26.1 mos [15.74-NR]

  • Safety

    Grade3AEs: Lipase increased (17.8%), maculopapular rash (11.1%), fatigue (11.1%), peripheral sensory neuropathy (4.4%)


    • J Clin Oncol 2023 41:1, 22-31

    Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

    http://doi.org/10.1200/JCO.22.01643

    Reviewed by Elvin Chalabiyev, MD on Apr 14, 2023